A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer

Non-Small Cell Lung Cancer Clinical Trial

Official title:

A Randomized Phase 3 Study of Two Doses of Alimta in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed a Prior Platinum-Containing Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00078260
• Other study ID #: 8433
• Secondary ID: H3E-MC-JMGX
• Status: Completed
• Phase: Phase 3
• Start date: December 2003
• Est. completion date: April 2008

Study information

• Verified date: September 2019
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purposes of this study are to determine:

• the safety of pemetrexed and any side effects that might be associated with it

• how much pemetrexed should be given to patients.

It is possible that information collected during this study will be analyzed by the Sponsor in the future to evaluate pemetrexed for other possible uses or for other medical or scientific purposes other than those currently proposed.

Although pemetrexed has been shown to be effective in some patients with non-small-cell lung cancer, pemetrexed might not have beneficial effects for all patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 589
• Est. completion date: April 2008
• Est. primary completion date: October 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of locally advanced or metastatic (Stage III or IV at entry) non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.

• Patients must have been previously treated with one platinum-containing chemotherapy regimen for locally advanced or metastatic disease. Patients are also eligible if they have received one platinum-based chemotherapy regimen as neoadjuvant or adjuvant chemotherapy, but must have received an additional chemotherapy regimen upon recurrence.

• No more than two prior systemic anti-cancer therapies will be allowed.

• Prior radiation therapy is allowed to less than 25% of the bone marrow. Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 2 weeks before study enrollment, and the patient must have recovered from the acute toxic effects of the treatment prior to study enrollment.

Exclusion Criteria:

• Pregnancy.

• Breast-feeding.

• Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.

• Inability to interrupt aspirin, or other nonsteroidal anti-inflammatory agents for a 5-day period.

• Inability or unwillingness to take folic acid or vitamin B12 supplementation.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-Small Cell Lung Cancer

Intervention

Drug:
• pemetrexed
A: 500 mg/m2, IV, q 21 days until disease progression B: 900 mg/m2, IV, q 21 days until disease progression

Locations

Country	Name	City	State
Turkey	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Ankara
Turkey	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Gaziantep

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

Turkey, 

References & Publications (1)

Cullen MH, Zatloukal P, Sörenson S, Novello S, Fischer JR, Joy AA, Zereu M, Peterson P, Visseren-Grul CM, Iscoe N. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metas — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival		baseline to date of death from any cause
Secondary	Progression free survival		baseline to measured progressive disease
Secondary	Tumor response rate		baseline to measured progressive disease
Secondary	Adverse events		every cycle

External Links

•   Lilly Clinical Trial Registry